AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 160 filers reported holding AERIE PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $282,000 | +89.3% | 18,628 | -6.1% | 0.00% | – |
| Q2 2022 | $149,000 | -19.9% | 19,845 | -2.9% | 0.00% | – |
| Q1 2022 | $186,000 | +42.0% | 20,443 | +9.3% | 0.00% | – |
| Q4 2021 | $131,000 | -40.5% | 18,700 | -3.3% | 0.00% | -100.0% |
| Q3 2021 | $220,000 | -13.4% | 19,336 | +22.0% | 0.00% | 0.0% |
| Q2 2021 | $254,000 | -11.5% | 15,854 | -1.1% | 0.00% | 0.0% |
| Q1 2021 | $287,000 | +26.4% | 16,033 | -4.7% | 0.00% | 0.0% |
| Q4 2020 | $227,000 | -13.0% | 16,826 | -24.2% | 0.00% | 0.0% |
| Q3 2020 | $261,000 | -23.2% | 22,206 | -3.6% | 0.00% | -50.0% |
| Q2 2020 | $340,000 | +10.0% | 23,024 | +0.5% | 0.00% | 0.0% |
| Q1 2020 | $309,000 | -27.3% | 22,899 | +30.2% | 0.00% | 0.0% |
| Q4 2019 | $425,000 | +106.3% | 17,585 | +63.9% | 0.00% | +100.0% |
| Q3 2019 | $206,000 | -10.8% | 10,726 | +120.9% | 0.00% | 0.0% |
| Q1 2019 | $231,000 | +4.5% | 4,856 | -20.6% | 0.00% | 0.0% |
| Q4 2018 | $221,000 | -17.8% | 6,115 | +39.8% | 0.00% | 0.0% |
| Q3 2018 | $269,000 | -2.5% | 4,375 | +7.0% | 0.00% | -50.0% |
| Q2 2018 | $276,000 | – | 4,087 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |